Philips Reports Results of Stellarex .035 Low-Dose Drug-Coated Balloon in Two Clinical Studies for Peripheral Arterial Disease

 Philips Reports Results of Stellarex .035 Low-Dose Drug-Coated Balloon in Two Clinical Studies for Peripheral Arterial Disease

Philips Reports Results of Stellarex .035 Low-Dose Drug-Coated Balloon in Two Clinical Studies for Peripheral Arterial Disease

Shots:

  • The ILLUMENATE & ILLUMENATE EU RCT studies results involve assessing of Stellarex .035 DCB vs uncoated balloons in patients with the peripheral arterial disease for 3yrs.
  • The ILLUMENATE & ILLUMENATE EU RCT studies results: @36mos. maintenance of blood flow through diseased arteries (64.2% & 67.5% vs 51.0% & 59.9%); mortality rate (10.1% & 9.4% vs 11.0% vs 8.5%) respectively
  • Stellarex .035 is a low-dose drug-coated balloon intended to restore and maintain blood flow in diseased femoral and popliteal arteries featuring EnduraCoat Technology and has received FDA’s approval in the US and CE marking in Europe

Click here to read full press release/ article | Ref: Philips | Image: Spectranetics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post